EXAI News and Press, Exscientia Limited From 02/08/24

2024-02-08 08:45:25 ET Hitek Global  ( HKIT ) +524% . CCSC Technology International  ( CCTG ) +110% . Bit Brother  ( BETS ) +74% . China SXT Pharmaceuticals  ( SXTC ) +69% . MicroCloud Hologram  ( HOLO ) +52% ...

Multicentre EXCYTE-2 study to evaluate precision medicine platform in patients with acute myeloid leukaemia Supports ongoing development of LSD1 inhibitor (EXS74539) currently in preclinical development Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-2...

2024-01-30 09:30:00 ET Summary MoneyShow presents top investment ideas for 2024 from their contributors. This year’s edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations tha...

2024-01-02 08:09:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Two factors –lower interest rates and the low valuation of many biotech stocks — are likely to result in many biotech companies being acquired in 2024. Lower interest rates wi...

Distinguished honour for Exscientia’s founder and Chief Executive Awarded in the 2024 New Year Honours List by HM King Charles III Follows multiple recent recognitions for outstanding personal achievements and those of Exscientia Professor Andrew Hopkins FRS FMedS...

2023-12-30 09:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-26 13:19:21 ET More on AbCellera Biologics, Absci, etc. Exscientia Looks Promising In AI-Driven Drug Development AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platf...

2023-12-22 17:56:28 ET Summary The biotech bear market has presented investment opportunities for investors to take meaningful stakes in public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months, but Gain Therapeutics' has found success usi...

The programme aims to design a potential best in class molecule by combining Exscientia's research platform with Sanofi's leading development expertise Exscientia eligible for additional upfront and research stage milestones on top of existing agreement Exscientia plc (Nasdaq: E...

2023-12-08 08:34:55 ET Summary Exscientia is a pharmaceutical company using AI-based precision engineering to revolutionize drug discovery and reduce drug creation by 70%. The company has strong financials, with a cash runway into 2026 and partnerships with industry giants such as...